Patient characteristics
| . | No. (%) . | |
|---|---|---|
| Sex | ||
| Female | 147 (45) | |
| Male | 177 (55) | |
| Tumor type | ||
| Nonfunctioning | 190 (59) | |
| Insulinoma | 54 (17) | |
| Gastrinoma | 43 (13) | |
| Glucagonoma | 19 (6) | |
| VIPoma | 15 (5) | |
| Cushing | 3 (1) | |
| Hereditary status | ||
| Sporadic | 274 (84) | |
| MEN1 | 43 (15) | |
| vHL | 4 (1) | |
| Surgery of primary tumor | 114 (35) | |
| WHO classification (n = 241) | ||
| I | 47 (20) | |
| II | 173 (71) | |
| III | 21 (9) | |
| Stage (n = 302) | ||
| I | 33 (11) | |
| IIa | 24 (8) | |
| IIb | 14 (5) | |
| IIIa | 9 (3) | |
| IIIb | 42 (14) | |
| IV | 180 (60) | |
| Referred from | ||
| Primary uptake area | 135 (42) | |
| External referral | 188 (58) | |
| Median size of primary tumor (cm) | 4.0 (range, 0.3-17) | |
| Median age at diagnosis, y | 53 (range, 12-86) | |
| Median chromogranin A at diagnosis (n = 139) | 3.7 × UNL (range, 0.4-1,280) | |
| Median BMI at diagnosis, kg/m2 (n = 155) | 24.0 (range, 15-42) | |
| . | No. (%) . | |
|---|---|---|
| Sex | ||
| Female | 147 (45) | |
| Male | 177 (55) | |
| Tumor type | ||
| Nonfunctioning | 190 (59) | |
| Insulinoma | 54 (17) | |
| Gastrinoma | 43 (13) | |
| Glucagonoma | 19 (6) | |
| VIPoma | 15 (5) | |
| Cushing | 3 (1) | |
| Hereditary status | ||
| Sporadic | 274 (84) | |
| MEN1 | 43 (15) | |
| vHL | 4 (1) | |
| Surgery of primary tumor | 114 (35) | |
| WHO classification (n = 241) | ||
| I | 47 (20) | |
| II | 173 (71) | |
| III | 21 (9) | |
| Stage (n = 302) | ||
| I | 33 (11) | |
| IIa | 24 (8) | |
| IIb | 14 (5) | |
| IIIa | 9 (3) | |
| IIIb | 42 (14) | |
| IV | 180 (60) | |
| Referred from | ||
| Primary uptake area | 135 (42) | |
| External referral | 188 (58) | |
| Median size of primary tumor (cm) | 4.0 (range, 0.3-17) | |
| Median age at diagnosis, y | 53 (range, 12-86) | |
| Median chromogranin A at diagnosis (n = 139) | 3.7 × UNL (range, 0.4-1,280) | |
| Median BMI at diagnosis, kg/m2 (n = 155) | 24.0 (range, 15-42) | |
Abbreviations: VIP, vasoactive intestinal peptide; vHL, von Hippel Lindau disease; UNL, upper normal limit.